BELLE‑3: a phase III study of buparlisib+fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment - Di Leo, A; Seok Lee, K; Ciruelos, E (San Antonio Breast Cancer Symposium, 2016)
San Antonio, TX, USA; Abstract